Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 3/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.50 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | DAO | P14920 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
| ▸ | DDO | Q99489 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7841259 | 0.87 | KDR (0.51) | KDRCHEK1FLT3KDM4EDAO | |
| SCHEMBL6510708 | 0.85 | KDR (0.50) | KDRCHEK1FLT3KDM4EDAO | |
| SCHEMBL7094486 | 0.85 | KDR (0.50) | KDRCHEK1FLT3KDM4EDAO | |
| SCHEMBL3735366 | 0.78 | KDR (0.56) | KDRCHEK1FLT3KDM4EDAO | |
| SCHEMBL71078 | 0.78 | KDR (0.56) | KDRCHEK1FLT3KDM4EDAO | |
| SCHEMBL7915702 | 0.78 | KDR (0.51) | KDRCHEK1FLT3KDM4EDAO | |
| Hydrochloric Acid SCHEMBL1713915 | 0.77 | KDR (0.54) | KDRCHEK1FLT3KDM4EDAO | |
| SCHEMBL2860216 | 0.77 | KDR (0.54) | KDRCHEK1FLT3KDM4EDAO | |
| SCHEMBL31310116 | 0.77 | KDR (0.54) | KDRCHEK1FLT3KDM4EDAO | |
| SCHEMBL9690611 | 0.75 | KDR (0.56) | KDRCHEK1FLT3KDM4EDAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030203910-A1 | Novel compounds for enhancing chemotherapy | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-10-30 | — | — | US | claimed |
| WO-1999043323-A1 | COMPOUNDS AND METHODS FOR CHEMOSENSITIZING MULTIDRUG RESISTANT CELLS | FOX CHASE CANCER CENTER (US) | 1999-09-02 | — | — | WO | claimed |
| WO-1997048708-A1 | DENDROAMIDE COMPOUNDS AND THEIR USE IN CHEMOSENSITIZING MULTIDRUG RESISTANT CELLS | FOX CHASE CANCER CENTER (US) | 1997-12-24 | — | — | WO | claimed |
| US-20230151432-A1 | KIF18A INHIBITORS FOR TREATMENT OF NEOPLASTIC DISEASES | AMGEN INC. (US) | 2023-05-18 | — | — | US | disclosed |
| EP-4136263-A1 | KIF18A INHIBITORS FOR TREATMENT OF NEOPLASTIC DISEASES | Amgen Inc. (US) | 2023-02-22 | — | — | EP | disclosed |
| CN-115667551-A | KIF18A inhibitors for the treatment of neoplastic diseases | 美国安进公司 | 2023-01-31 | — | — | CN | disclosed |
| WO-2021211549-A1 | KIF18A INHIBITORS FOR TREATMENT OF NEOPLASTIC DISEASES | AMGEN INC. (US) | 2021-10-21 | — | — | WO | disclosed |
| WO-2017013172-A1 | NOVEL INHIBITORS OF P-GLYCOPROTEIN | STICHTING KATHOLIEKE UNIVERSITEIT (NL) | 2017-01-26 | — | — | WO | disclosed |
| US-20160244457-A1 | SELECTIVE EFFLUX INHIBITORS AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATMENT | UNIV KANSAS (US) | 2016-08-25 | — | — | US | disclosed |
| US-20150328180-A1 | Composition | SLOTERVAART PARTICIPATIES BV (NL) | 2015-11-19 | — | — | US | disclosed |
| US-9089544-B2 | Composition | SLOTERVAART PARTICIPATIES BV (NL) | 2015-07-28 | — | — | US | disclosed |
| WO-2001040305-A1 | NOVEL ABCB9 TRANSPORTER AND USES THEREOF | ACTIVE PASS PHARMACEUTICALS, INC. (CA) | 2001-06-07 | — | — | WO | disclosed |
| WO-2001014414-A2 | HUMAN ABC2 TRANSPORTER AND USES THEREOF | ACTIVEPASS PHARMACEUTICALS, INC. (CA) | 2001-03-01 | — | — | WO | disclosed |
| WO-2000024390-A9 | METHOD AND COMPOSITION FOR MODULATING AMYLOIDOSIS | UNIV BRITISH COLUMBIA (CA) | 2000-12-07 | — | — | WO | disclosed |
| WO-2000024390-A1 | METHOD AND COMPOSITION FOR MODULATING AMYLOIDOSIS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2000-05-04 | — | — | WO | disclosed |
| EP-0979086-A2 | METHOD AND COMPOSITION FOR MODULATING AMYLOIDOSIS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2000-02-16 | — | — | EP | disclosed |
| WO-1999043323-A1 | COMPOUNDS AND METHODS FOR CHEMOSENSITIZING MULTIDRUG RESISTANT CELLS | FOX CHASE CANCER CENTER (US) | 1999-09-02 | — | — | WO | disclosed |
| US-5869650-A | POTENTIATE CYTOTOXICITY OF ANTICANCER DRUGS | FOX CHASE CANCER CENTER (US) | 1999-02-09 | — | — | US | disclosed |
| WO-1998048784-A2 | METHOD AND COMPOSITION FOR MODULATING AMYLOIDOSIS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 1998-11-05 | — | — | WO | disclosed |
| WO-1997048708-A1 | DENDROAMIDE COMPOUNDS AND THEIR USE IN CHEMOSENSITIZING MULTIDRUG RESISTANT CELLS | FOX CHASE CANCER CENTER (US) | 1997-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203910-A1 | Novel compounds for enhancing chemotherapy | ABCB1, ABCB11, ABCC1 | KDR 1044/4885CHEK1 1688/4885FLT3 2258/4885 |
| US-20230151432-A1 | KIF18A INHIBITORS FOR TREATMENT OF NEOPLASTIC DISEASES | KIF18A, KIF18B, KIF20A | KDR 3888/4885CHEK1 330/4885FLT3 3779/4885 |
| US-20160244457-A1 | SELECTIVE EFFLUX INHIBITORS AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATMENT | ABCB1, ABCG2, ABCC5 | KDR 1140/4885CHEK1 868/4885FLT3 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.